Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab
Normal serology enhances the protection of DORIS and LLDAS against severe and renal SLE flares, possible reflecting deeper states of disease control. Patients with recently active disease who meet clinical targets but have persistently abnormal serology may require close monitoring to minimize flare-risk.
Authors
- Julius Lindblom
- George K Bertsias (ORCID: https://orcid.org/0000-0001-5299-1406)
- Alvaro Gómez (ORCID: https://orcid.org/0000-0001-9618-1755)
- Ioannis Parodis (ORCID: https://orcid.org/0000-0002-4875-5395)
Institutions
- Karolinska University Hospital (SE)
- University of Crete (GR)
- Örebro University (SE)
- Karolinska Institutet (SE)
- Institute of Molecular Biology and Biotechnology (BG)
- Foundation for Research and Technology Hellas (GR)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-02-22
- DOI
- https://doi.org/10.1093/rheumatology/keaf107
- Citations
- 5
- Primary Topic
- Systemic Lupus Erythematosus Research
- Type
- article
- Field-Weighted Citation Impact
- 8.34